Within 24 Hours, an mRNA Booster Reshapes the Immune System—and Naive CD4 T Cells May Hint at Breakthrough Infection Risk

Within a single day of receiving an mRNA COVID-19 booster shot, the human immune system undergoes a dramatic and measurable transformation. A new study published in Frontiers in Cellular and Infection Microbiology has captured this rapid remodeling in unprecedented detail, using high-dimensional mass cytometry to profile the blood of 124 vaccine recipients and uncovering a surprising signal: subtle changes in naive CD4 T-cell markers within the first 24 hours were associated with whether participants later experienced a documented breakthrough infection with SARS-CoV-2.

The research, led by Xuanjing Yu, Xinyu Jiang, and colleagues at Yunnan University’s Bio-X Center for Interdisciplinary Innovation and Yunnan Vaccine Laboratory, took advantage of a randomized clinical trial of mRNA booster vaccines. The team selected an outcome-balanced subset of 124 participants—62 who later developed a documented COVID-19 case during follow-up and 62 who did not—matched across sex, vaccine product, and age category. Peripheral blood mononuclear cells collected immediately before vaccination (Day 0) and again 24 hours later (Day 1) were stained with a metal-conjugated antibody cocktail and analyzed by mass cytometry, a technique that detects individual metal isotopes rather than overlapping fluorescent signals, allowing researchers to measure dozens of markers on millions of single cells simultaneously.

Seventeen major immune-cell populations were manually gated from the resulting data, spanning the full spectrum of circulating immunity: classical, intermediate, and non-classical monocytes; myeloid and plasmacytoid dendritic cells; natural killer cells; gamma-delta T cells; NKT-like cells; naive, central memory, effector memory, and terminally differentiated effector memory subsets of both CD4 and CD8 T cells; and B cells. Cell abundances were transformed using a centered log-ratio (CLR) method to account for the compositional nature of blood-cell counts, and marker expression was summarized as sample-level median arcsinh-transformed intensities. Composite module scores were built from markers associated with type I interferon signaling, Th1 chemokines, pro-inflammatory cytokines, CCL2–CCR2 axis, antigen presentation, activation, and cytotoxicity, alongside individual readouts for global H3K27ac—a histone modification marking active promoters and enhancers—and m6A, the most prevalent internal modification of eukaryotic mRNA.

The results revealed a strikingly rapid, lineage-specific redistribution of circulating immune cells. Within 24 hours, classical and intermediate monocytes showed the largest positive shifts in relative abundance, consistent with mobilization of the myeloid compartment in response to vaccine-derived signals. In contrast, plasmacytoid dendritic cells, natural killer cells, and selected CD8 and unconventional T-cell populations showed prominent negative shifts. The four major CD4 T-cell populations—naive, central memory, effector memory, and terminally differentiated effector memory—remained comparatively stable on this relative-composition scale. These changes were accompanied by distinct, lineage-restricted alterations in intracellular and phenotypic markers: classical monocytes displayed prominent changes in MCP-1, arginase-1, and H3K27ac; intermediate monocytes showed changes in CCR2, CD38, and IL-4; pDCs exhibited changes in granzyme B and CXCR3; and NK cells showed marked alterations in CD69 and CD56.

Crucially, the team found that early changes in global m6A and H3K27ac signals correlated with relative-abundance changes in selected innate and T-cell populations. m6A changes correlated positively with classical and intermediate monocyte abundance but inversely with pDC and NK-cell abundance. H3K27ac changes were also inversely correlated with pDC and NK-cell abundance. Within the T-cell compartment, both m6A and H3K27ac changes were inversely related to CD4 naive T-cell abundance, while m6A changes were positively associated with CD4 effector memory abundance but inversely associated with CD8 naive and CD8 central memory abundance. These correlations suggest that global modification signals track distinct differentiation-state trajectories across the immune landscape, though the authors caution that correlation does not establish causation.

When the researchers examined whether these early cellular and molecular changes predicted subsequent neutralizing-antibody responses, the picture became more nuanced. Both groups showed broad increases in serum neutralization against a panel of SARS-CoV-2 variants—including the prototype strain, Alpha, Beta, BA.4/5, BF.7, BQ.1.1, XBB.1.5, XBB.1.16, XBB.1.9.1, and JN.1—measured longitudinally through Day 180 using a vesicular stomatitis virus-based pseudovirus neutralization assay. However, after excluding antibody measurements obtained on or after documented breakthrough infection and applying Benjamini–Hochberg correction across the complete 340-test family of cell population–marker–strain combinations, no early H3K27ac- or m6A-associated signal change remained significantly associated with Day 14 or Day 180 neutralizing-antibody responses. The strongest nominal association—an inverse relationship between early H3K27ac change in CD4 central memory cells and the BF.7 response—did not survive correction.

The most compelling finding emerged when the team compared early immune trajectories between participants who subsequently developed documented breakthrough infection and those who did not. Major-cell abundance trajectories did not differ significantly between the two groups, indicating that the broad redistribution of circulating immune populations was shared regardless of later infection status. However, a focused screen of 13 prespecified feature readouts across all 17 major immune-cell populations—comprising 221 tests—revealed five feature–cell-population combinations that remained significant after global multiple-testing correction. Four of these were concentrated within the CD4 naive T-cell compartment: the IFN–Th1 chemokine-associated, cytotoxic–Th1-associated, and CCL2–CCR2-associated marker scores, and the m6A-associated readout. The fifth involved the cytotoxic–Th1-associated score in CD4 central memory cells. Relative to non-BTI participants, individuals who subsequently developed breakthrough infection showed smaller—more negative—Day 0-to-Day 1 changes in each of these features.

The authors emphasize that these composite scores represent combinations of measured markers rather than direct functional assays. Signal intensity varied substantially among constituent markers within CD4 naive cells: granzyme B was robustly detected, while MCP-1, CXCL9, and CD57 showed measurable intermediate-level signals, but IFN-γ, CD86, and CXCR3 exhibited relatively low absolute intensities. Unsupervised clustering further resolved 11 phenotypic subclusters within the CD4 naive compartment, demonstrating substantial internal heterogeneity, though the significant associations were identified at the total population level and cannot yet be assigned to specific subclusters. A sensitivity analysis adjusting for age, sex, and vaccine product using HC3 robust standard errors confirmed the direction of the BTI-associated differences for all four CD4 naive features.

The study’s implications extend beyond the immediate findings. By demonstrating that dynamic early immune states—captured within 24 hours of vaccination—can capture outcome-associated variation not evident from major-cell abundance alone, the work supports a broader paradigm shift in systems vaccinology: rather than relying on static baseline measurements or single downstream readouts, researchers may need to characterize the full temporal trajectory of immune responses to understand why some individuals remain protected while others experience breakthrough infection. The authors note that breakthrough infection is influenced by factors beyond measured immune features, including exposure intensity, circulating viral variants, mucosal immunity, and behavioral factors, and that illness-triggered surveillance may have missed asymptomatic infections. Future studies integrating antigen-specific assays, absolute cell counts, single-cell RNA sequencing, chromatin-accessibility profiling, and transcript-resolved m6A analysis will be necessary to define the biological pathways underlying these early CD4 naive T-cell associations and to establish their clinical relevance as correlates of vaccine-response heterogeneity.

Subject of Research: Mass cytometry study of early immune remodeling after mRNA booster vaccination and its association with breakthrough infection

Article Title: Mass cytometry of early immune remodeling after mRNA booster vaccination reveals exploratory CD4 naive T-cell associations with documented breakthrough infection

Article References: Yu, X., Jiang, X., Xue, Y., Ji, Y., Li, C., Zhang, Z. S., & Cheng, R. (2026). Mass cytometry of early immune remodeling after mRNA booster vaccination reveals exploratory CD4 naive T-cell associations with documented breakthrough infection. Frontiers in Cellular and Infection Microbiology, 16, Article 1966930. https://doi.org/10.3389/fcimb.2026.1966930

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1966930

Keywords: mRNA vaccine, mass cytometry, breakthrough infection, CD4 naive T cells, H3K27ac, m6A, Mass, cytometry, early, immune, remodeling, mRNA